{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:26:15Z","timestamp":1773285975502,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,3,29]],"date-time":"2005-03-29T00:00:00Z","timestamp":1112054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:\u2002<\/jats:bold>\n                    Accumulating evidence suggests that combination therapy using oral antidiabetic agents with different mechanisms of action may be highly effective in achieving and maintaining target blood glucose levels. The aim of our study is to evaluate the differential effect on glucose and lipid parameters of the association between glimepiride plus metformin and rosiglitazone plus metformin in patients affected by type 2 diabetes and metabolic syndrome.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Patients were enroled, evaluated and followed at two Italian centres. We evaluated 99 type 2 diabetic patients with metabolic syndrome (48 males and 47 females; 23 males and 24 females, aged 52\u2003\u00b1\u20035 with glimepiride; 25 males and 23 females, aged 54\u2003\u00b1\u20034 with cglitazone). All were required to have been diagnosed as being diabetic for at least 6\u2003months and did not have glycaemic control with diet and oral hypoglycaemic agents such as sulphonylureas or metformin, both to the maximum tolerated dose. All patients took a fixed dose of metformin, 1500\u2003mg\/day. We administered glimepiride (2\u2003mg\/day) or rosiglitazone (4\u2003mg\/day) in a randomized, controlled, double\u2010blind clinical study. We evaluated body mass index (BMI), glycaemic control, lipid profile [total cholesterol (TC), low\u2010density lipoprotein\u2010cholesterol (LDL\u2010C), high\u2010density lipoprotein\u2010cholesterol and triglycerides] and lipoprotein parameters [apolipoprotein A\u2010I and apolipoprotein B (Apo B)] during 12\u2003months of this treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    A total of 95 patients completed the study. Significant BMI decrease was observed at 12\u2003months in glimepiride and rosiglitazone group (p\u2003&lt;\u20030.05 and p\u2003&lt;\u20030.01 respectively) as well as of glycated haemoglobin decrease (p\u2003&lt;\u20030.05 and p\u2003&lt;\u20030.01 respectively), mean fasting plasma glucose and postprandial plasma glucose levels (p\u2003&lt;\u20030.05 and p\u2003&lt;\u20030.01 respectively). A decrease in fasting plasma insulin and postprandial plasma insulin at 12\u2003months (p\u2003&lt;\u20030.05 and p\u2003&lt;\u20030.01 respectively) compared with the baseline value in rosiglitazone group was observed. Furthermore, homeostasis model assessment index improvement was obtained only at 9 and 12\u2003months (p\u2003&lt;\u20030.05 and p\u2003&lt;\u20030.01 respectively) compared with the baseline value in rosiglitazone group. Significant TC, LDL\u2010C and Apo B improvement (p\u2003&lt;\u20030.05 respectively) was present in glimepiride group after 12\u2003months compared with the baseline values, and these variations were significant (p\u2003&lt;\u20030.05) between groups. Of the 95 patients who completed the study, 8.5% of patients in glimepiride group and 12.5% of patients in rosiglitazone group had side\u2010effects (p\u2003=\u2003not significant). Four patients had transient side\u2010effects in glimepiride group and six patients in rosiglitazone group. Altogether, we did not have statistically significant changes in transaminases.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    The rosiglitazone\u2013metformin association significantly improve the long\u2010term control of all insulin\u2010resistance\u2010related parameters in comparison with the glimepiride\u2013metformin\u2010treated group. On the other side, glimepiride treatment is associated to a slight improvement in cholesterolaemia, not observed in the rosiglitazone\u2010treated patients.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2005.00480.x","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T05:03:01Z","timestamp":1138770181000},"page":"197-205","source":"Crossref","is-referenced-by-count":31,"title":["Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double\u2010blind, clinical trial"],"prefix":"10.1111","volume":"8","author":[{"given":"G.","family":"Derosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Gaddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. N.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Salvadeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ghelfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F. G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,29]]},"reference":[{"issue":"6","key":"e_1_2_5_2_2","first-page":"5","article-title":"Is metformin more than an oral hypoglycaemic agent?","volume":"29","author":"Vague P","year":"2003","journal-title":"Diabetes Metab"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2244"},{"key":"e_1_2_5_4_2","first-page":"854","article-title":"Effect of intensive blood\u2010glucose control with metformin on complications in overweight patients with type 2 diabetes","volume":"253","author":"UK Prospective Diabetes Study (UKPDS) Group.","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"issue":"1","key":"e_1_2_5_6_2","first-page":"S1","article-title":"American Diabetes Association: clinical practice recommendations 2004","volume":"27","author":"American Diabetes Association.","year":"2004","journal-title":"Diabetes Care"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0936-0"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00338-7"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2007.S368"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.4.699"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.7.1179"},{"issue":"4","key":"e_1_2_5_12_2","first-page":"406","article-title":"Thiazolidinediones in diabetes: current status and future outlook","volume":"4","author":"Camp HS","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.6.1364"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00663.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00258.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III)","volume":"285","author":"National Cholesterol Education Program (NCEP) Expert Panel.","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"e_1_2_5_17_2","first-page":"S44","article-title":"Nutrition recommendations and principles for people with diabetes mellitus (Position Statement)","volume":"24","author":"American Diabetes Association.","year":"2001","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_2_5_18_2","first-page":"S21","article-title":"Screening for diabetes (Position Statement)","volume":"24","author":"American Diabetes Association.","year":"2001","journal-title":"Diabetes Care"},{"key":"e_1_2_5_19_2","first-page":"i","volume":"894","author":"World Health Organization.","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"key":"e_1_2_5_20_2","first-page":"151","article-title":"1999 World Health Organization\u2010International Society of Hypertension Guidelines for the Management of Hypertension","volume":"17","author":"Guidelines Subcommittee.","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.635569"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.1999.00166.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01225569"},{"key":"e_1_2_5_25_2","first-page":"121","article-title":"Enzymatische bestimmung des gesamtcholesterins mit dem greiner selective analyzer (GSA II)","volume":"15","author":"Klose S","year":"1978","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-091304-6.50036-7"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103182"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald WT","year":"1972","journal-title":"Clin Chem"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1016\/S0021-9258(18)38083-9","article-title":"The amphipathic a\u2010helical repeats of apolipoprotein A\u2010I are responsible for binding of high density lipoproteins to HepG2 cells","volume":"266","author":"Leblond L","year":"1991","journal-title":"J Biol Chem"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0022-2275(20)38572-2","article-title":"Human apolipoprotein: analysis of internal repeats and homology with other apolipoproteins","volume":"28","author":"De Loof H","year":"1987","journal-title":"J Lipid Res"},{"key":"e_1_2_5_31_2","volume-title":"Statistical principles in experimental design","author":"Winer BJ","year":"1971"},{"issue":"6","key":"e_1_2_5_32_2","first-page":"53","article-title":"Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes","volume":"29","author":"Despres JP","year":"2003","journal-title":"Diabetes Metab"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(03)00911-7"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00258.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.2.283"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.12.3479"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80090-5"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90074-4"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.264"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363130-00004"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2005.00480.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2005.00480.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:20:56Z","timestamp":1761884456000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2005.00480.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,29]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1463-1326.2005.00480.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2005.00480.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,29]]}}}